Several patent registrations are possible to be used by the Government of the Republic of Indonesia as regulated under Article 109 to 120 of the Indonesian Patent Law. However, there are 2 main determinants that will need to be met first:

  1. The patent is related to national security and defence, such as explosive materials, firearms, and explosive ammunition; or
  2. There is an urgent need to use the patent for the benefit of the people of the Republic of Indonesia. For instance, in the event of an epidemic of a disease where the cure may only be possible by using registered patents; in the field of agriculture, the use of registered patents by the Government may be needed to counter crop failure caused by pests and/or natural disasters.

The use of registered patents by the Government should also be established by a Presidential Decree. The use should also be done with no profit gaining purpose in mind and it is only limited within a certain period. Please note that the use may be extended unilaterally by the Government. The extension should be supported by the recommendation from relevant ministries. For instance, if it is related to health issues, then the extension of the use of registered patents by the Government can only be done after receiving a recommendation from the Ministry of Health. The Patent Holders will always be kept in the loop with regard to the use of their patents in Indonesia by the Government since the Government will send the copy of the Presidential Decree to the Patent Holders.

The use of registered patents by the Government related to national security and defence include:

  1. Firearms;
  2. Ammunitions
  3. Military grade explosives;
  4. Interceptions;
  5. Surveillance;
  6. Espionage;
  7. Encoding device and analysis encoding devices;
  8. Other country’s defence and security process and/or devices.

Whereas the use of registered patents by the Government in the event of an urgent need for the benefit of the people include:

  1. Pharmaceutical and/or biotechnology products with unaffordable price tags and/or which are needed to counter an epidemic that may result in fatalities of many people, cause significant disabilities, and is considered as a global health issue;
  2. Chemical and/or biotechnology products related to agriculture that are needed for food security;
  3. Animal drugs that are needed to counter plaguing pests and/or animal diseases; and/or
  4. Process and/or products to counter natural disasters and/or environmental disasters.

Please note that during the use of registered patents related to national security and defence, the Patent Holders will not be able to exercise its exclusive rights to use, sell, import, lease, assign, produce, and prohibit other parties without their prior consent. Whereas the use of registered patents by the Government in the event of an urgent need for the benefit of the people does not diminish the rights of the Patent Holders to use, sell, import, lease, assign, produce, and prohibit other parties without their prior consent.

Registered patents which can threaten or endanger Indonesia’s defence and national security can only be used and exercised by the Government. If the Government has not used them yet, the Patent Holders should obtain prior approval to use from the Government. During the use of the registered patents by the Government, the Patent Holders is exempted from paying annuity fees for its patents.

The use of registered patents by the Government is recorded in the Patent Gazette and is published in electronic or conventional media. Please note that their decision to use registered patents is final and binding, hence no possible legal avenue to dispute or challenge the use of registered patents by the Patent Holders.

Legal notice

The contents of this publication, current at the date of publication set out above, are for reference purposes only. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication. Please contact [email protected] or contact us via our website should you have any question regarding this article.